Foresite Capital Fund V L.P. 13D and 13G filings for Theseus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-11-24 4:23 pm Unchanged | 2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 5,494,621 12.400% | 0 (Unchanged) | Filing |
| 2023-07-19 2:41 pm Purchase | 2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 5,494,621 12.600% | 700,000 (+14.60%) | Filing |
| 2023-01-03 4:36 pm Purchase | 2022-12-29 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 4,794,621 12.400% | 500,000 (+11.64%) | Filing |
| 2022-06-13 4:24 pm Purchase | 2022-06-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 4,294,621 11.100% | 613,069 (+16.65%) | Filing |
| 2021-10-18 1:15 pm Purchase | 2021-10-07 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 3,681,552 9.800% | 3,681,552 (New Position) | Filing |